Suppr超能文献

尾加压素II与动脉粥样硬化

Urotensin II and atherosclerosis.

作者信息

Loirand Gervaise, Rolli-Derkinderen Malvyne, Pacaud Pierre

机构信息

Inserm U533, Nantes F-44000, France.

出版信息

Peptides. 2008 May;29(5):778-82. doi: 10.1016/j.peptides.2007.08.024. Epub 2007 Sep 2.

Abstract

Urotensin II, through its interaction with its UT receptor, is a potent vasoactive peptide in humans and in several animal models. Recent studies have demonstrated elevated plasma U-II levels in patients with atherosclerosis and coronary artery disease. U-II is expressed in endothelial cells, smooth muscle cells and infiltrating macrophages of atherosclerotic human coronary arteries. UT receptor expression is up-regulated by inflammatory stimuli. Activation of UT receptor by U-II stimulates endothelial and smooth muscle cell proliferation and monocytes chemotaxis. Therefore, in addition to its primary vasoactive effect, these observations suggest a role of U-II and UT receptor in the initiation and/or progression of atherosclerosis.

摘要

尾加压素II通过与UT受体相互作用,在人类和多种动物模型中是一种强效血管活性肽。最近的研究表明,动脉粥样硬化和冠状动脉疾病患者的血浆尾加压素II水平升高。尾加压素II在人类动脉粥样硬化冠状动脉的内皮细胞、平滑肌细胞和浸润的巨噬细胞中表达。UT受体的表达受炎症刺激上调。尾加压素II激活UT受体可刺激内皮细胞和平滑肌细胞增殖以及单核细胞趋化性。因此,除了其主要的血管活性作用外,这些观察结果提示尾加压素II和UT受体在动脉粥样硬化的发生和/或发展中起作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验